Neuren Pharmaceuticals Limited

ASX:NEU ISIN:NZNEUE0001S8

Neuren Pharmaceuticals is a biopharmaceutical company developing novel therapeutics in the fields of brain injury, neurological diseases and conditions, and metabolic disorders. The Neuren portfolio comprises eight product families targeting markets with large unmet needs and limited competition. Neuren has three clinical-stage molecules - Glypromate(R), MotivaTM and NNZ-2566 -focused on a range of acute and chronic neurological conditions. For more information visit:
http://www.neurenpharma.com 
 

News

Neuren Pharmaceuticals (ASX:NEU) To Get US$5.5M Additional Funding for US Army Clinical Trial of NNZ-2566

🕔9/5/2008 9:36:53 AM 4313

Neuren Pharmaceuticals (ASX:NEU)(PINK:NURPF) announced that the Company has been informed that an additional US$5.5 million in funding will be made available by the US Army for the Company's planned Phase II clinical trial of NNZ-2566 in traumatic brain injury (TBI). With the previously announced grant of US$4 million to cover direct costs of the study, this results in a total commitment of approximately US$10 million.

Read Full Article

Conference Call Half Year 2008 Results

🕔7/22/2008 10:03:00 PM 2099

adidas AG Dear journalist,

Read Full Article

MPH Ventures Continues To Significantly Expand

🕔7/22/2008 6:03:00 PM 2101

MPH Ventures Corp. (OTC: MPSFF) Suite 2230 - 885 West Georgia Street, Vancouver, BC, Canada, V6C 3E8 www.mphventurescorp.com

Read Full Article

Granville Baird Acquires Meier Vakuumtechnik And Makes Major Investment In The Alternative Energy Market

🕔7/21/2008 7:33:00 PM 3261

Granville Baird GmbH Bocholt/ Hamburg, 21.07.2008. Private equity investor Granville Baird acquires a majority stake in Meier Vakuumtechnik GmbH as part of a management buy-out. Meier specializes in the development, production and sales of equipment for manufacturing photovoltaic panels. Considerable worldwide growth is expected in this market as electricity generation from solar sources will continue to expand.

Read Full Article

Neuren Pharmaceuticals (ASX: NEU) Announce Glypromate(R) and NNZ-2566 Included in 10 Most Promising Neuroscience Projects by Windhover

🕔7/21/2008 2:06:36 PM 4307

Neuren Pharmaceuticals (ASX:NEU)(PINK:NURPF) announced today that Glypromate(R) and NNZ-2566 for neuroprotection in cardiopulmonary bypass and traumatic brain injury (TBI) have been selected as one of the Top 10 most promising neuroscience projects available for partnering by an independent committee assembled by Windhover Information, a leading provider of business information products and services to senior executives in the pharmaceutical, biotechnology, and medical device industries.

Read Full Article

Neuren Pharmaceuticals Limited ASX: NEU - Further Validation of NNZ-2566 as a Traumatic Brain Injury Treatment - Mr David Clarke, CEO

🕔2/14/2007 11:43:00 AM 2749

Neuren Pharmaceuticals Limited (ASX: NEU) - Further Validation of NNZ-2566 as a Traumatic Brain Injury Treatment - Mr David Clarke, CEO; Boardroomradio is pleased to announce that Neuren Pharmaceuticals Limited (ASX: NEU) has published an audio file.

Read Full Article
###

4,046 COMPANY PROFILE VIEWS

  • This Page Viewed: (Last 7 Days: 2) (Last 30 Days: 9) (Since Published: 4046) 

Company Data

    Headquarters
  • Level 2, 57 Wellington Street
    Freemans Bay, Auckland
    New Zealand
  • Telephone
  • +64 (9) 529 3940 
  • Fax
  • +64 (9) 361 7981 
  • Principal Sector
  • Health & Pharm 
  • Principal Industry
  • Biotechnology 
  • Listed
  • 2005/02/03 
  • Homepage
  • www.neurenpharma.com

More News Results

  • 2024/03/12: Application for quotation of securities - NEU*
  • 2024/02/29: 2023 Results webinar*
  • 2024/02/29: Neuren reports profit of $157 million for 2023*
  • 2024/02/29: Appendix 4E and 2023 full year accounts*
  • 2024/02/29: Neuren 2023 results investor webinar on 29 February 2024*
  • 2024/02/28: DAYBUE net sales US$87.1 million in Q4 2023*
*refer to company website